Bicara Therapeutics Inc. Common Stock (BCAX) is a publicly traded Healthcare sector company. As of August 26, 2026, BCAX trades at $24.60 with a market cap of $1.56B and a P/E ratio of -9.83. BCAX moved +4.22% today. Year to date, BCAX is +50.06%; over the trailing twelve months it is +117.14%. Its 52-week range spans $7.80 to $30.99. Analyst consensus is strong buy with an average price target of $33.33. Rallies surfaces BCAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for BCAX combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $24.60 |
| Market Cap | $1.56B |
| P/E Ratio | -9.83 |
| EPS | $-2.52 |
| Dividend Yield | 0.00% |
| 52-Week High | $30.99 |
| 52-Week Low | $7.80 |
| Volume | 328.02K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-137.95M |
| Gross Margin | 0.00% |
12 analysts cover BCAX: 0 strong buy, 9 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $33.33.